{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:46:22Z","timestamp":1794584782320,"version":"4.9.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41571-025-01011-3","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T11:08:16Z","timestamp":1741950496000},"page":"371-378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2070-3614","authenticated-orcid":false,"given":"Sophie M.","family":"Ernst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7685-051X","authenticated-orcid":false,"given":"Mihaela","family":"Aldea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9699-4860","authenticated-orcid":false,"given":"Jan H.","family":"von der Th\u00fcsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianus J.","family":"de Langen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert F.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthe S.","family":"Paats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6662-2951","authenticated-orcid":false,"given":"Joachim G. J. V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0936-7338","authenticated-orcid":false,"given":"Laura","family":"Mezquita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2087-4963","authenticated-orcid":false,"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5090-8189","authenticated-orcid":false,"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-875X","authenticated-orcid":false,"given":"Jordi","family":"Remon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrikus J.","family":"Dubbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6105-182X","authenticated-orcid":false,"given":"Anne-Marie C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"1011_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41586-023-06225-y","volume":"619","author":"SA Cohen","year":"2023","unstructured":"Cohen, S. A., Liu, M. C. & Aleshin, A. Practical recommendations for using ctDNA in clinical decision making. Nature 619, 259\u2013268 (2023).","journal-title":"Nature"},{"key":"1011_CR2","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1001\/jamaoncol.2022.4457","volume":"8","author":"MG Krebs","year":"2022","unstructured":"Krebs, M. G. et al. Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: a narrative review. JAMA Oncol. 8, 1830\u20131839 (2022).","journal-title":"JAMA Oncol."},{"key":"1011_CR3","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","volume":"33","author":"J Pascual","year":"2022","unstructured":"Pascual, J. et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann. Oncol. 33, 750\u2013768 (2022).","journal-title":"Ann. Oncol."},{"key":"1011_CR4","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","volume":"16","author":"C Rolfo","year":"2021","unstructured":"Rolfo, C. et al. Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer. J. Thorac. Oncol. 16, 1647\u20131662 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"1011_CR5","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","volume":"36","author":"JD Merker","year":"2018","unstructured":"Merker, J. D. et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J. Clin. Oncol. 36, 1631\u20131641 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1011_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20","author":"E Heitzer","year":"2019","unstructured":"Heitzer, E., Haque, I. S., Roberts, C. E. S. & Speicher, M. R. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat. Rev. Genet. 20, 71\u201388 (2019).","journal-title":"Nat. Rev. Genet."},{"key":"1011_CR7","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","volume":"11","author":"C Alix-Panabi\u00e8res","year":"2021","unstructured":"Alix-Panabi\u00e8res, C. & Pantel, K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 11, 858\u2013873 (2021).","journal-title":"Cancer Discov."},{"key":"1011_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105074","volume":"102","author":"SM Ernst","year":"2024","unstructured":"Ernst, S. M. et al. Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis. eBioMedicine 102, 105074 (2024).","journal-title":"eBioMedicine"},{"key":"1011_CR9","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1016\/j.jtho.2023.05.013","volume":"18","author":"A Chour","year":"2023","unstructured":"Chour, A. et al. Severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-PD(L)1 and sotorasib therapy in KRAS(G12C)-mutant lung cancer. J. Thorac. Oncol. 18, 1408\u20131415 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"1011_CR10","volume":"2","author":"P Begum","year":"2021","unstructured":"Begum, P., Goldin, R. D., Possamai, L. A. & Popat, S. Severe immune checkpoint inhibitor hepatitis in KRAS G12C-mutant NSCLC potentially triggered by sotorasib: case report. JTO Clin. Res. Rep. 2, 100213 (2021).","journal-title":"JTO Clin. Res. Rep."},{"key":"1011_CR11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","volume":"28","author":"D Jackman","year":"2010","unstructured":"Jackman, D. et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J. Clin. Oncol. 28, 357\u201360 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1011_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35961-y","volume":"14","author":"J Chmielecki","year":"2023","unstructured":"Chmielecki, J. et al. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nat. Commun. 14, 1070 (2023).","journal-title":"Nat. Commun."},{"key":"1011_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35962-x","volume":"14","author":"J Chmielecki","year":"2023","unstructured":"Chmielecki, J. et al. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nat. Commun. 14, 1071 (2023).","journal-title":"Nat. Commun."},{"key":"1011_CR14","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","volume":"36","author":"SS Ramalingam","year":"2018","unstructured":"Ramalingam, S. S. et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J. Clin. Oncol. 36, 841\u2013849 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1011_CR15","doi-asserted-by":"publisher","first-page":"JCO2400581","DOI":"10.1200\/JCO.24.00581","volume":"42","author":"BJ Solomon","year":"2024","unstructured":"Solomon, B. J. et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN Study. J. Clin. Oncol. 42, JCO2400581 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1011_CR16","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge, D. R. et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J. Thorac. Oncol. 16, 2091\u20132108 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"1011_CR17","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.annonc.2021.08.2151","volume":"32","author":"AJ Schoenfeld","year":"2021","unstructured":"Schoenfeld, A. J. et al. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Ann. Oncol. 32, 1597\u20131607 (2021).","journal-title":"Ann. Oncol."},{"key":"1011_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","volume":"599","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y. et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature 599, 679\u2013683 (2021).","journal-title":"Nature"},{"key":"1011_CR19","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad, M. M. et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N. Engl. J. Med. 384, 2382\u20132393 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1011_CR20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","volume":"36","author":"H Rizvi","year":"2018","unstructured":"Rizvi, H. et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J. Clin. Oncol. 36, 633\u2013641 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1011_CR21","first-page":"PO.20.00321","volume":"5","author":"JC Thompson","year":"2021","unstructured":"Thompson, J. C. et al. Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy. JCO Precis. Oncol. 5, PO.20.00321 (2021).","journal-title":"JCO Precis. Oncol."},{"key":"1011_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.960459","volume":"13","author":"J Peng","year":"2022","unstructured":"Peng, J. et al. Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1\/PD-L1 blockade. Front. Immunol. 13, 960459 (2022).","journal-title":"Front. Immunol."},{"key":"1011_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-57218-9","volume":"10","author":"S Hwang","year":"2020","unstructured":"Hwang, S. et al. Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Sci. Rep. 10, 643 (2020).","journal-title":"Sci. Rep."},{"key":"1011_CR24","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jtho.2024.04.007","volume":"9","author":"SM Ernst","year":"2024","unstructured":"Ernst, S. M. et al. Clinical utility of circulating tumor DNA in patients with advanced KRAS(G12C)-mutated NSCLC treated with sotorasib. J. Thorac. Oncol. 9, 995\u20131006 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"1011_CR25","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-23-0795","volume":"29","author":"CP Paweletz","year":"2023","unstructured":"Paweletz, C. P. et al. Early changes in circulating cell-free KRAS G12C predict response to adagrasib in KRAS mutant non-small cell lung cancer patients. Clin. Cancer Res. 29, 3074\u20133080 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1011_CR26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne, P. A. et al. Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation. N. Engl. J. Med. 387, 120\u2013131 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1011_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107897","volume":"194","author":"Q Zheng","year":"2024","unstructured":"Zheng, Q. et al. NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: a prospective, multicenter study in China. Lung Cancer 194, 107897 (2024).","journal-title":"Lung Cancer"},{"key":"1011_CR28","doi-asserted-by":"publisher","first-page":"9074","DOI":"10.1200\/JCO.2023.41.16_suppl.9074","volume":"41","author":"H Yu","year":"2023","unstructured":"Yu, H. et al. Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib. J. Clin. Oncol. 41, 9074\u20139074 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1011_CR29","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/s41416-024-02607-9","volume":"130","author":"JC Laguna","year":"2024","unstructured":"Laguna, J. C. et al. Incidental pathogenic germline alterations detected through liquid biopsy in patients with solid tumors: prevalence, clinical utility and implications. Br. J. Cancer 130, 1420\u20131431 (2024).","journal-title":"Br. J. Cancer"},{"key":"1011_CR30","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00583","volume":"7","author":"M Aldea","year":"2023","unstructured":"Aldea, M. et al. Liquid biopsies for circulating tumor DNA detection may reveal occult hematologic malignancies in patients with solid tumors. JCO Precis. Oncol. 7, e2200583 (2023).","journal-title":"JCO Precis. Oncol."},{"key":"1011_CR31","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.annonc.2021.09.002","volume":"32","author":"M Aldea","year":"2021","unstructured":"Aldea, M. et al. Detection of additional occult malignancy through profiling of ctDNA in late-stage cancer patients. Ann. Oncol. 32, 1642\u20131645 (2021).","journal-title":"Ann. Oncol."},{"key":"1011_CR32","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1126\/science.aaa6806","volume":"348","author":"I Martincorena","year":"2015","unstructured":"Martincorena, I. et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348, 880\u2013886 (2015).","journal-title":"Science"},{"key":"1011_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41586-023-05874-3","volume":"616","author":"W Hill","year":"2023","unstructured":"Hill, W. et al. Lung adenocarcinoma promotion by air pollutants. Nature 616, 159\u2013167 (2023).","journal-title":"Nature"},{"key":"1011_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jjcc.2022.02.001","volume":"81","author":"T Misaka","year":"2023","unstructured":"Misaka, T. et al. Clonal hematopoiesis and cardiovascular diseases: role of JAK2V617F. J. Cardiol. 81, 3\u20139 (2023).","journal-title":"J. Cardiol."},{"key":"1011_CR35","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","volume":"25","author":"P Razavi","year":"2019","unstructured":"Razavi, P. et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat. Med. 25, 1928\u20131937 (2019).","journal-title":"Nat. Med."},{"key":"1011_CR36","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jmoldx.2023.09.004","volume":"25","author":"CM Lockwood","year":"2023","unstructured":"Lockwood, C. M. et al. Recommendations for cell-free DNA assay validations: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists. J. Mol. Diagn. 25, 876\u2013897 (2023).","journal-title":"J. Mol. Diagn."},{"key":"1011_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1373\/clinchem.2019.306837","volume":"66","author":"R Lampignano","year":"2020","unstructured":"Lampignano, R. et al. Multicenter evaluation of circulating cell-free DNA extraction and downstream analyses for the development of standardized (pre)analytical work flows. Clin. Chem. 66, 149\u2013160 (2020).","journal-title":"Clin. Chem."},{"key":"1011_CR38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","volume":"18","author":"M Ignatiadis","year":"2021","unstructured":"Ignatiadis, M., Sledge, G. W. & Jeffrey, S. S. Liquid biopsy enters the clinic \u2014 implementation issues and future challenges. Nat. Rev. Clin. Oncol. 18, 297\u2013312 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1011_CR39","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-23-3321","volume":"30","author":"CD Rolfo","year":"2024","unstructured":"Rolfo, C. D. et al. Measurement of ctDNA tumor fraction identifies informative negative liquid biopsy results and informs value of tissue confirmation. Clin. Cancer Res. 30, 2452\u20132460 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1011_CR40","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature11219","volume":"486","author":"LA Diaz Jr.","year":"2012","unstructured":"Diaz, L. A. Jr. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537\u201340 (2012).","journal-title":"Nature"},{"key":"1011_CR41","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.2011.38.3224","volume":"30","author":"KY Su","year":"2012","unstructured":"Su, K. Y. et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 30, 433\u201340 (2012).","journal-title":"J. Clin. Oncol."},{"key":"1011_CR42","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm.4040","volume":"22","author":"AN Hata","year":"2016","unstructured":"Hata, A. N. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262\u20139 (2016).","journal-title":"Nat. Med."},{"key":"1011_CR43","doi-asserted-by":"publisher","first-page":"7854","DOI":"10.1158\/0008-5472.CAN-06-1951","volume":"66","author":"M Inukai","year":"2006","unstructured":"Inukai, M. et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 66, 7854\u20138 (2006).","journal-title":"Cancer Res."},{"key":"1011_CR44","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1097\/JTO.0b013e3182653d7f","volume":"7","author":"Y Fujita","year":"2012","unstructured":"Fujita, Y. et al. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J. Thorac. Oncol. 7, 1640\u20131644 (2012).","journal-title":"J. Thorac. Oncol."},{"key":"1011_CR45","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1097\/JTO.0b013e31829f691f","volume":"8","author":"X Ye","year":"2013","unstructured":"Ye, X. et al. High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact? J. Thorac. Oncol. 8, 1118\u201320 (2013).","journal-title":"J. Thorac. Oncol."},{"key":"1011_CR46","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","volume":"13","author":"MV Negrao","year":"2023","unstructured":"Negrao, M. V. et al. Comutations and KRASG12C inhibitor efficacy in advanced NSCLC. Cancer Discov. 13, 1556\u20131571 (2023).","journal-title":"Cancer Discov."},{"key":"1011_CR47","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","volume":"11","author":"N Tanaka","year":"2021","unstructured":"Tanaka, N. et al. Clinical acquired resistance to KRAS(G12C) inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discov. 11, 1913\u20131922 (2021).","journal-title":"Cancer Discov."},{"key":"1011_CR48","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2018.4305","volume":"5","author":"C Aggarwal","year":"2019","unstructured":"Aggarwal, C. et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 5, 173\u2013180 (2019).","journal-title":"JAMA Oncol."},{"key":"1011_CR49","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1001\/jamaoncol.2015.4482","volume":"2","author":"AG Sacher","year":"2016","unstructured":"Sacher, A. G. et al. Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer. JAMA Oncol. 2, 313\u2013320 (2016).","journal-title":"JAMA Oncol."},{"key":"1011_CR50","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra24 (2014).","journal-title":"Sci. Transl. Med."},{"key":"1011_CR51","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jtho.2019.11.024","volume":"15","author":"M Aldea","year":"2020","unstructured":"Aldea, M. et al. Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression. J. Thorac. Oncol. 15, 383\u2013391 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"1011_CR52","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1158\/1078-0432.CCR-23-2693","volume":"30","author":"PM Kasi","year":"2024","unstructured":"Kasi, P. M. et al. Circulating tumor DNA enables sensitive detection of actionable gene fusions and rearrangements across cancer types. Clin. Cancer Res. 30, 836\u2013848 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1011_CR53","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jtho.2020.10.156","volume":"16","author":"W Li","year":"2021","unstructured":"Li, W. et al. Potential unreliability of uncommon ALK, ROS1, and RET genomic breakpoints in predicting the efficacy of targeted therapy in NSCLC. J. Thorac. Oncol. 16, 404\u2013418 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"1011_CR54","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.3390\/cancers13092265","volume":"13","author":"EG Pizzutilo","year":"2021","unstructured":"Pizzutilo, E. G. et al. Liquid biopsy for small cell lung cancer either de novo or transformed: systematic review of different applications and meta-analysis. Cancers 13, 2265 (2021).","journal-title":"Cancers"},{"key":"1011_CR55","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccell.2024.01.001","volume":"42","author":"S Heeke","year":"2024","unstructured":"Heeke, S. et al. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell 42, 225\u2013237.e5 (2024).","journal-title":"Cancer Cell"},{"key":"1011_CR56","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.2016.71.9096","volume":"35","author":"JK Lee","year":"2017","unstructured":"Lee, J. K. et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J. Clin. Oncol. 35, 3065\u20133074 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1011_CR57","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","volume":"14","author":"M Offin","year":"2019","unstructured":"Offin, M. et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J. Thorac. Oncol. 14, 1784\u20131793 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"1011_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-06369-3","volume":"12","author":"T Vaclova","year":"2022","unstructured":"Vaclova, T. et al. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition. Sci. Rep. 12, 2699 (2022).","journal-title":"Sci. Rep."},{"key":"1011_CR59","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","volume":"21","author":"MJ Niederst","year":"2015","unstructured":"Niederst, M. J. et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin. Cancer Res. 21, 3924\u20133933 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1011_CR60","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41571-022-00660-y","volume":"19","author":"A Tivey","year":"2022","unstructured":"Tivey, A. et al. Circulating tumour DNA \u2014 looking beyond the blood. Nat. Rev. Clin. Oncol. 19, 600\u2013612 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1011_CR61","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo, J. et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 29, 1895\u20131902 (2018).","journal-title":"Ann. Oncol."},{"key":"1011_CR62","first-page":"PO.17.00011","volume":"2017","author":"D Chakravarty","year":"2017","unstructured":"Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. 2017, PO.17.00011 (2017).","journal-title":"JCO Precis. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01011-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01011-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01011-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T08:00:42Z","timestamp":1745481642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01011-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1011"],"URL":"https:\/\/doi.org\/10.1038\/s41571-025-01011-3","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"27 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A. has received research funding from Amgen, AstraZeneca and Sandoz. A.J.d.L. has acted as a consultant of AstraZeneca, BMS, Boehringer Ingelheim, Daiichi\/Sankyo, Lilly, MSD and Pfizer and received research funding from AstraZeneca, BMS, Boehringer Ingelheim and MSD. E.F.S. has acted as a consultant of AstraZeneca, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Janssen, Merck, MSD, Roche, Sanofi and Takeda, acted as a speaker for Boehringer Ingelheim, Daiichi Sankyo and participated in Data and Safety Monitoring Boards for DSI, Mythis and Taiho. M.S.P. has acted as a consultant and\/or adviser of Amgen, Eli Lilly, Janssen, Merck and Pfizer. J.G.J.V.A. has acted as a consultant of AstraZeneca, CureVac, Danone and MSD, has acted as a speaker on behalf of BMS, Eli Lilly and MSD, has received research funding from AstraZeneca, Danone and Genmab, is listed on patents relating to allogenic tumour cell lysates, combination immune-oncology drug regimens and biomarkers for immunotherapy, has unpaid leadership roles as Treasurer of the IASLC and is a board member of IMIG and holds stock options in Amphera. L.M. has acted as a consultant of Janssen, MSD+, Roche and Takeda, has acted as a speaker for AstraZeneca, Janssen, MSD, Pfizer, Radonova, Roche and Takeda, has received research funding from Amgen, AstraZeneca, Gilead and Inivata and received travel support from AstraZeneca, BMS, Janssen, Roche and Takeda. S.P. has acted as a consultant of Anhaert Therapeutics, Amgen, Arcus Biosciences, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Ellipses, Erasca, Gilead, GSK, Guardant Health, IO Biotech, Janssen, Lilly, Merck KGaA, Mirati, MSD, Novocure, Novartis, Pfizer, Pharmamar, Pierre Fabr, Regeneron, Roche, Sanofi, Takeda and Turning Point Therapeutics, received speaker\u2019s fees from Amgen, AstraZeneca, Bayer, Gilead, Guardant Health, Janssen, Merck KGaA, Novocure, Pharmamar, Pfizer, Roche and Takeda, received travel support from Gilead and has unpaid leadership roles in ALK positive UK, BTOG, ETOP\/IBCSG Foundation Board, Lung Cancer Europe, Mesothelioma Applied Research Foundation and Ruth Strauss Foundation. B.B. has acted as a consultant and\/or adviser of Abbvie, Amgen, AstraZeneca, Biontech SE, Beigene, Beijing Avistone Biotechnology, BMS, CureVac AG, Eli Lilly, Ellipses pharma, F. Hoffmann-La Roche, Foghorn Therapeutics, Genmab, Immunocore, Janssen, Pharmamar, MSD, Ose Immunotherapeutics, Owkin, Regeneron, Sanofi Aventis and Takeda and has acted as a speaker for Abbvie, AstraZeneca, BMS, Daichii Sankyo, Lilly, MSD, Ose Immunotherapeutics, Sanofi Aventis and Servier. J.R. has acted as a speaker for Johnson & Johnson and MSD, has received travel support from MSD and has an unpaid leadership role as Secretary of the EORTC lung cancer group. C.R. has acted as a consultant of Abbvie, ACC MED, ASCO Plenary Series, Amgen, Bayer, Blueprint, Cadence, Diverse Health Hub, Eisai, GME, Guardant Health, Invitae, Janssen Scientific Affairs, Lungevity, Medical Educator Consortium, Merck, MSHO, MH Live Events, Nadirex, Novartis, Novocure, Regeneron and Thermo Fisher, has acted as a speaker for AstraZeneca, Aptitude Health, Boehringer Ingelheim, COR2ED, Intellisphere LLC, IDEOLogy, MSD and Roche and has received research funding from Pfizer and Roche. H.J.D. has acted as an adviser of Abbvie, Astellas, AstraZeneca, Janssen and MSD and has acted as a speaker for AstraZeneca, BMS, GSK, Illumina, Johnson & Johnson, MSD and Roche, has received research funding from AstraZeneca, HederaDx, Illumina, MSD and OncoDNA. A.-M.C.D. has acted as an adviser and\/or consultant of Abbvie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi, Eli Lilly, Johnson & Johnson, Mirati, Pfizer and Roche and has acted as a speaker for Amgen, Eli Lilly and Johnson & Johnson, has participated in Independent Data Monitoring Committees for Roche and Takeda and has an unpaid leadership role as chair of the EORTC lung cancer group. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}